Christiane Gerke, PhD, is the Program Director at IVI’s Europe Regional Office in Stockholm, Sweden and is responsible for developing new programs and leading the vaccine development projects in Europe. Christiane has more than 15 years of experience in vaccine research and development in industry and academia with focus on translating science into innovative vaccine candidates through pre-clinical development and manufacturing up to Phase II clinical trials and/or partnerships.
Before joining IVI, Christiane served at the Institut Pasteur in Paris, France, as Head of Vaccine Programs and Vaccine Innovation Development, supporting a portfolio of 20+ vaccine candidates, e.g. against Shigella, COVID-19, plague, malaria, dengue, or Lassa fever. In addition, she co-led the new Vaccinology and Immunotherapy Initiative. Christiane started her career in vaccines at Novartis Vaccines Institute for Global Health, Siena, Italy, where she spearheaded the development of a vaccine candidate against shigellosis based on a novel technology of outer membrane particles called GMMA (Generalized Modules for Membrane Antigens).
Christiane received her PhD in Microbial Genetics at the University of Tübingen (Germany) and trained as post doc at Stanford University (USA) in immunology and host-pathogen interactions.